Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

The Delhi High Court on Tuesday disposed of a public interest litigation (PIL) raising alarm over the off-label and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Guest blog by Joachim Bjørkmann from Ministry of Foreign Affairs Denmark as part of our #UnleashInnovation week 2025.

Robert F. Kennedy Jr. announces HHS campaign for wearables as affordable alternatives to medications, highlighting how they ...

(Reuters) -U.S. Health Secretary Robert F. Kennedy Jr. said on Tuesday that the Department of Health and Human Services plans ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million ...